Brought to you by 
GSK options several boron drug candidates from Anacor
05 Oct 2012
Executive Summary
Anacor Pharmaceuticals (topical compounds for fungal, bacterial, and inflammatory diseases) has given GlaxoSmithKline options to exclusively license worldwide rights to several of its boron-containing antiviral and antibacterial candidates in a six-year deal that may be extended up to two years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK options several boron drug candidates from Anacor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice